Lack of opiate receptor involvement in centrally induced calcitonin analgesia

Braga, P. C.; Ferri, Sergio Solbes; Santagostino, A.; Olgiati, Vincenzo R.; Pecile, A.

doi:10.1016/0024-3205(78)90362-4

Cited by 153 publications

(34 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exceptions were e9 endorphin and substance P, but as compared with the KDs estimated for their own receptors (23,25), higher concentrations were required to inhibit binding of 12.I-Calcitonin. Thus, the results obtained indicate that brain tissue is equipped with ultimobronchial calcitonin like-specific receptors and that these receptors act in the mediation of the behavioral effect of centrally given calcitonins, such as analgesia (5)(6)(7)(8)(9), tremor (9) and decreased eating (10).…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Specific binding of 125I-salmon calcitonin to rat brain: Regional variation and calcitonin specificity.

et al. 1981

View full text Add to dashboard Cite

Abstract-Rat brain particulate fraction was found to contain binding sites for 1251-Salmon Calcitonin-I (1251-SCT). Maximum binding occurred in the physiological pH range of 7.25-7.5. The binding reaction proceeded in a temperature-dependent manner. Binding sites were broadly distributed among the various rat brain regions and considerable regional differences existed in the affinity and density as detected by Scatchard analysis. The highest affinity was recorded in the case of the hypothalamus and the lowest in the case of the cerebellum. The KD (nM) and Bmax (pmole/mg protein) estimated for the binding to four regions were as follows: hypothalamus: 1.4 and 0.19, midbrain, hippocampus plus striatum: 1.5 and 0.08, pons plus medulla oblongata: 3.0 and 0.15 and cerebellum: 8.3 and 0.20. Using a particulate fraction of rat brain void of cerebellum and cortices, a binding assay for calcitonins was developed. Binding of '251-SCT was inhibited by unlabeled salmon, [Asu1,']-eel** and porcine calcitonins in a dose-dependent manner and the IC50s were 2.0, 8.0 and 30 nM, respectively. The IC50s were comparable to those estimated using a kidney particulate fraction. Human calcitonin, 3-endorphin and substance P were weak inhibitors of the binding. Other peptides, drugs and putative neuro transmitters tested (totally 23 substances) failed to inhibit the binding at concentrations of 1.0 SaM. The physiological significance of brain binding sites for calcitonin, with the possiblity that the brain may possess endogenous ligands for these sites are discussed.In the research field of neuroendocrinology,

show abstract

Section: Discussionmentioning

confidence: 89%

“…A suggestion has been made that the binding sites might mediate some behavioral effects of centrally administered calcitonins (5)(6)(7)(8)(9)(10). In addition, we detected in rat brain, the presence of a calcitonin-like activity, in terms of the activity to inhibit ultimobronchial calcitonin binding to the brain tissue (11).…”

mentioning

confidence: 89%

Specific binding of 125I-salmon calcitonin to rat brain: Regional variation and calcitonin specificity.

et al. 1981

View full text Add to dashboard Cite

show abstract

“…[16][17][18][19] A nonopiate analgesic pathway has been suggested as calcitonin induced analgesic effect is not modified by opioids antagonists. 20 Other pathways suggested so far increases in the plasma beta-endorphin levels at the hypothalamus and/or the pituitary level, involvement of the serotonergic system. [21][22][23] The present study shows good analgesia and increases in the duration of the first dose of postoperative analgesia with increasing dose of salmon calcitonin from 50IU to 100IU.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of two different doses of intrathecal calcitonin, a randomized controlled study

2018

View full text Add to dashboard Cite

Background: Adjuvants play an important role in enhancing the quality of anesthesia and also in reducing the requirement of primary anesthetic and its related adverse events. Calcitonin is one such adjuvant. But there is still uncertainty regarding the appropriate dose of calcitonin to achieve maximum analgesic efficacy and safety. The current study is conducted to add to the existing evidence on the subject and was aimed to compare the efficacy and safety of two different doses of calcitonin as an adjuvant in patients undergoing spinal anesthesia.Methods: A prospective randomized controlled double-blind trial was conducted in the Department of Anesthesiology and Intensive Care, Sir Sunderlal Hospital, Banaras Hindu University from May 2006 to May 2007. A total of 80 participants aged between 18 to 60 years, with ASA I and II physical status, undergoing infra-umbilical surgeries were randomly allocated to one of the 4 intervention groups. All the 4 intervention groups received 0.5% bupivacaine (H) 3ml as a primary anesthetic agent. Group I and III received 50 IU and 100 IU salmon calcitonin as an adjuvant. Group II received placebo and group IV (control) received no adjuvant. Pinprick test, Bromage scale and 10-point Visual analog scale (VAS) were used to measure the efficacy.Results: All the study groups were comparable with respect to all baseline variables. The time interval to the first dose of analgesia was longest in 100 I.U. calcitonin group, followed by 50 I.U. calcitonin group, placebo control group. The mean duration of analgesia (in minutes) among group I (100I.U. calcitonin) was 230.00±92.39, 159.25±21.59 among group II (Placebo), 161.50±31.20 among group III (50 I.U. calcitonin) and 142.75±20.22 among group IV. Considering group IV (control group) as base line. The differences of duration of analgesia (in minutes) in group I, group II and group III with baseline value (group IV) were statistically significant (P value <0.05). Even though the proportion of subjects developing adverse events was slightly higher in 100 I.U calcitonin groups compared to other groups, they were minor adverse events and were managed appropriately. There were no significant differences across the study groups in terms of hemodynamic stability.Conclusions: Salmon calcitonin as adjuvant increases the duration of postoperative analgesia. Even though the there slightly higher incidence of adverse events with 100 I.U calcitonin they are minor and the risk-benefit ratio favors calcitonin use. To make a categorical recommendation on the appropriate dose, there is further need for large-scale studies and pooled analysis.

show abstract

“…However, two differences have been reported. Repeated central administration of calcitonin does not induce tolerance (Braga, Ferri, Santagostino, Olgiati & Pecile, 1978) and Braga et al, (1978) have shown that calcitonin is not antagonized by the opiate antagonist, naloxone. This has also been shown using levallorphan .…”

Section: When 15t [85sr]-labelled Microspheres Werementioning

confidence: 99%

Proceedings of the British Pharmacological Society

1981

British J Pharmacology

View full text Add to dashboard Cite

Lack of opiate receptor involvement in centrally induced calcitonin analgesia

Cited by 153 publications

References 7 publications

Specific binding of 125I-salmon calcitonin to rat brain: Regional variation and calcitonin specificity.

Specific binding of 125I-salmon calcitonin to rat brain: Regional variation and calcitonin specificity.

Efficacy and safety of two different doses of intrathecal calcitonin, a randomized controlled study

Proceedings of the British Pharmacological Society

Contact Info

Product

Resources

About